Mabwell Stages $547 Million IPO on STAR Board for Antibody Portfolio

Mabwell ( Shanghai ) Bioscience completed a $547 million IPO on Shanghai 's STAR Board. Established in 2017, Mabwell is a clinical-stage antibody developer with 15 assets in its pipeline: three are in BLA stage, three in pivotal trials and six in Phase I/II trials. The company's lead candidates are biosimilars. It develops therapies for indications in auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases. The company has a wholly-owned US subsidiary, Mabwell Therapeutics, in San Diego . Mabwell's shares have fallen 22% below their IPO price. More details.... Stock Symbol: (SHA: 688062) Share this with colleagues: // //